SCHEMBL5258546

SCHEMBL5258546

CCOc1cccc(-c2ccc(CC(=O)Nc3ccc4c(C=C(C(N)=O)c5ccccc5)c[nH]c4n3)cc2)c1

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 1/20 0.43
FGFR2 P21802 1/20 0.43
FGFR3 P22607 1/20 0.43
KMT2A Q03164 4/20 0.41
ICMT O60725 3/20 0.41
WNT3A P56704 3/20 0.41
RIOK2 Q9BVS4 1/20 0.40
RXRA P19793 1/20 0.39
RXRB P28702 1/20 0.39
AAK1 Q2M2I8 1/20 0.39
MEN1 O00255 3/20 0.39
RAB9A P51151 1/20 0.38
PTGER2 P43116 2/20 0.37
MGLL Q99685 1/20 0.37
HDAC6 Q9UBN7 1/20 0.37
SLC6A2 P23975 1/20 0.37
SLC6A3 Q01959 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5258541 1.00 FGFR1 (0.43) FGFR1FGFR2FGFR3KMT2AICMT
SCHEMBL5263516 0.90 WNT3A (0.37) FGFR1FGFR2FGFR3KMT2AICMT
SCHEMBL5263514 0.90 WNT3A (0.37) FGFR1FGFR2FGFR3KMT2AICMT
SCHEMBL5259071 0.89 KMT2A (0.46) KMT2AWNT3ARIOK2MEN1RAB9A
SCHEMBL5259070 0.89 KMT2A (0.46) KMT2AWNT3ARIOK2MEN1RAB9A
SCHEMBL5258458 0.85 KMT2A (0.39) KMT2AWNT3AMEN1RAB9ASLC6A2
SCHEMBL5258453 0.85 KMT2A (0.39) KMT2AWNT3AMEN1RAB9ASLC6A2
SCHEMBL5259908 0.84 ADORA2A (0.40) KMT2AMEN1RAB9A
SCHEMBL5259914 0.84 ADORA2A (0.40) KMT2AMEN1RAB9A
SCHEMBL5315071 0.84 ADORA2A (0.40) KMT2AMEN1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1309590-B1 AZAINDOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS ANTITUMOR AGENTS PFIZER ITALIA SRL (IT) 2007-09-19 EP claimed
US-20030004350-A1 AZAINDOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS ANTITUMOR AGENTS PHARMACIA & UPJOHN (IT) 2003-01-02 US claimed
US-6335342-B1 1H-PYRROLO(2,3-B)PYRIDINE DERIVATIVES; ANTICARCINOGENIC, ANTIMETASTASIS, ANTITUMOR AND ANTIPROLIFERATIVE AGENTS PHARMACIA & UPJOHN S.P.A. (IT) 2002-01-01 US claimed
EP-1309590-B1 AZAINDOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS ANTITUMOR AGENTS PFIZER ITALIA SRL (IT) 2007-09-19 EP disclosed
US-20030004350-A1 AZAINDOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS ANTITUMOR AGENTS PHARMACIA & UPJOHN (IT) 2003-01-02 US disclosed
US-6486322-B1 Azaindole derivatives, process for their preparation, and their use as antitumor agents PHARMACIA ITALIA S.P.A. (IT) 2002-11-26 US disclosed
US-6335342-B1 1H-PYRROLO(2,3-B)PYRIDINE DERIVATIVES; ANTICARCINOGENIC, ANTIMETASTASIS, ANTITUMOR AND ANTIPROLIFERATIVE AGENTS PHARMACIA & UPJOHN S.P.A. (IT) 2002-01-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030004350-A1 AZAINDOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS ANTITUMOR AGENTS FFAR4, AZI2, CNKSR1 FGFR1 201/4885FGFR2 192/4885FGFR3 633/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.